ArticleFrontiers in molecular biosciences2026
Optimized RTX strategy plus structured glucocorticoid tapering for primary membranous nephropathy: a multicenter propensity score-matched cohort study.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Incidence and implications of anti-rituximab antibodies in nephropathies and other immune-mediated diseases: a narrative review.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Standard rituximab (RTX) regimens for primary membranous nephropathy (PMN) may result in subtherapeutic RTX exposure within 2-3 months due to altered pharmacokinetics, potentially contributing to delayed remission, incomplete immunologic control, and relapse. We evaluated whether an exposure-optimized RTX strategy combined with structured glucocorticoid tapering was associated with improved clinical and immunologic outcomes in PMN. Methods: This multicenter retrospective study included 182 PMN patients with nephrotic syndrome (2020-2025). After 1:2 propensity score matching, 75 patients were analyzed: an exposure-optimized strategy group (RTX 375 mg/m Results: At 6 months, the GC/MRTX group had higher RTX concentrations (median 7.46 vs. 0.07 μg/mL, p = 0.020) and a higher proportion of patients with RTX concentrations ≥2 μg/mL (60.0% vs. 21.1%, p = 0.022). Anti-RTX antibodies were detected only in the SRTX group (11%). At 12 months, GC/MRTX was associated with higher CR (64.0% vs. 22.0%, p < 0.001), higher complete immunological remission (80% vs. 42%, p = 0.002), and shorter time to CR (9.0 vs. 18.4 months, p < 0.001). NCR at 12 months was 88.0% versus 70.0% (p = 0.085). Over follow-up, GC/MRTX showed higher cumulative CR (p < 0.001) and NCR (p = 0.036) and lower relapse (0% vs. 18.4%, p = 0.026). In refractory PMN (n = 51), GC/MRTX achieved higher 12-month CR (52.63% vs. 18.75%, p = 0.012) and complete immunological remission (89.47% vs. 34.38%, p = 0.001). Safety profiles were comparable. Conclusion: In this propensity score-matched multicenter cohort, an exposure-optimized strategy combining interval RTX dosing, structured glucocorticoid tapering, and TDM-guided redosing was associated with higher and earlier remission, deeper immunologic response, and lower relapse compared with the standard RTX monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.